Journal
LANCET ONCOLOGY
Volume 10, Issue 6, Pages 628-635Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S1470-2045(09)70037-3
Keywords
-
Categories
Funding
- K U Leuven [05/15]
- Geconcerteerde onderzoeksactie [05/19]
- Fonds voor wetenschappelijk onderzoek (FWO) [G.0486.08]
Ask authors/readers for more resources
Most mycoplasmas are present as commensals, colonising the mucosa of our respiratory and gastrointestinal tract. Experimental data suggest that the long-term association of certain mycoplasma species with mammalian cells might favour host-cell transformation and malignancy. Moreover, increased mycoplasma infection has been noted in several cancers. Despite efforts to develop target-specific anticancer drugs, current cancer treatment still relies on the use of nucleobase or nucleoside-based analogues. Here, we provide experimental evidence that nucleoside-metabolising catabolic enzymes expressed by mycoplasmas substantially compromise the efficacy of nucleoside antimetabolites used in the treatment of cancer. We also suggest potential methods for improving future chemotherapy by suppressing mycoplasma-mediated catabolism of the anticancer nucleoside analogues.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available